Abstract：
BACKGROUND:Notoriously the treatment of multiple sclerosis (MS) is based on the use of several different drugs, characterized by a diverse mechanism of action, efficacy and safety. Recently, progress has been made towards developing new oral immunotherapies, and dimethyl fumarate is the third oral agent approved for the treatment of relapsing-remitting forms. CASE:A 24-year-old patient, affected by relapsing remitting multiple sclerosis, started treatment in December 2014 with dimethyl fumarate. The common side effects (flushing and gastrointestinal events) of dimethyl fumarate occurred at the beginning of treatment, but resolved after 1 month. Six months later, the patient presented with serious recrudescence of the gastrointestinal event. In addition to this symptom, he had developed acute omphalitis-a very rare infection in adults. CONCLUSION:The pathogenic role of dimethyl fumarate to induce this rare infection was probably related to changes in immunological surveillance as well as to the irritant effect of this agent on the gastrointestinal epithelium. Therefore, post-marketing studies in clinical practice are still needed to provide the necessary long-term safety data.
journal_name
Mult Scler Relat Disordjournal_title
Multiple sclerosis and related disordersauthors
Lorefice L,Fenu G,Cabras F,Frau J,Coghe GC,Loi L,Marrosu MG,Cocco Edoi
10.1016/j.msard.2016.03.009subject
Has Abstractpub_date
2016-05-01 00:00:00pages
65-7eissn
2211-0348issn
2211-0356pii
S2211-0348(16)30027-Xjournal_volume
7pub_type
杂志文章abstract：OBJECTIVES:We aimed to estimate the incidence and prevalence of chronic lung disease (CLD), including asthma and chronic obstructive pulmonary disease, in the MS population versus a matched cohort from the general population. METHODS:We used population-based administrative data from four Canadian provinces to identify...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2016.05.009
更新日期：2016-07-01 00:00:00
abstract：BACKGROUND:Multiple sclerosis (MS) is a chronic inflammatory demyelinating autoimmune disease of the central nervous system (CNS) with axonal degeneration as major determinant of neurological disability. Assessment of unmyelinated retinal nerve fibers using optical coherence tomography (OCT) may be useful for diagnosin...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2018.11.003
更新日期：2019-01-01 00:00:00
abstract：BACKGROUND:Fatigue is a complex and disabling symptom of Multiple Sclerosis (MS); however, there is conflicting evidence of the relationship between fatigue and clinical features of MS. Furthermore, few studies have considered these relationships specifically in a progressive MS population. AIMS:(1) estimate the preva...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2019.01.011
更新日期：2019-02-01 00:00:00
abstract：:Multiple sclerosis (MS) is an inflammatory, demyelinating, neurodegenerative, immune-mediated disease primarily diagnosed in early adulthood. Multiple sclerosis mostly impacts women of reproductive potential, with pregnancy and birth outcomes being major concerns for many patients. While there is ample evidence that t...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章,评审
doi：10.1016/j.msard.2019.04.003
更新日期：2019-07-01 00:00:00
abstract：:Multiple sclerosis is a chronic inflammatory and neurodegenerative disease of the central nervous system, and it is one of the most common neurological cause of disability in young adults. It is known that several factors contribute to increase the risk of development and pathogenesis of multiple sclerosis, nonetheles...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章,评审
doi：10.1016/j.msard.2020.102189
更新日期：2020-09-01 00:00:00
abstract：BACKGROUND:Neuromyelitis Optica Spectrum Disorder (NMOSD), commonly characterized by affecting optic nerves and spinal cord can be regarded as one of uncommon diseases of the central nervous system. Although the evidence presented in the literature supports cognitive impairments, psychological aspects of the disease an...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2020.102128
更新日期：2020-07-01 00:00:00
abstract：BACKGROUND:Pain can interfere with the daily functioning of persons with multiple sclerosis (PwMS). Furthermore, beliefs about pain and activity engagement are reliably associated with persons' experience of chronic pain. This study aimed to explore the extent to which different aspects of PwMS' activity engagement is ...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2019.101882
更新日期：2020-02-01 00:00:00
abstract：:Myelin oligodendrocyte glycoprotein (MOG) antibody (MOG -Ab) positive cases can have a focal encephalitis like presentation. Many reports of anti N-methyl-D-aspartate receptor (NMDAR) encephalitis have documented simultaneous coexistence of MOG-Ab which is explained by the coexpression of NMDA receptors and MOG on oli...
journal_title：Multiple sclerosis and related disorders
pub_type： 信件
doi：10.1016/j.msard.2020.102468
更新日期：2020-11-01 00:00:00
abstract：BACKGROUND:To determine and compare comorbidity levels in the multiple sclerosis (MS) population in Poland using a matched cohort from the general population. METHODS:We compared our database (standardized medical histories and medical records) from a MS center at the Department of Neurology, Medical University of Bia...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2020.102051
更新日期：2020-06-01 00:00:00
abstract：OBJECTIVE:Review cases of positive neurologic phenomena initiated or worsened with dalfampridine in patients with multiple sclerosis. BACKGROUND:Oral, extended release dalfampridine (4-aminopyridine or 4-AP) is a potassium-channel blocker approved for the treatment of gait impairment in multiple sclerosis (MS). The en...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2013.05.003
更新日期：2014-01-01 00:00:00
abstract：BACKGROUND:Neuromyelitis optica spectrum disorder (NMOSD) is a complex disease characterized by a severe inflammation of the central nervous system (CNS). This disease typically manifests with recurrent optic neuritis (ON) and acute transverse myelitis (ATM). The clinical and radiological spectrum of NMOSD is little kn...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2020.102208
更新日期：2020-09-01 00:00:00
abstract：:Randomized placebo-controlled clinical trials have been considered the most rigorous method of evaluating the efficacy of novel treatment interventions. The first effective disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS) were approved in the 1990s after a number of pivotal placebo-...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章,评审
doi：10.1016/j.msard.2016.03.019
更新日期：2016-05-01 00:00:00
abstract：INTRODUCTION:All people with progressive MS in the United Kingdom should have access to physiotherapy through the National Health Service (NHS). However levels of access and delivery are unknown. Furthermore there is no research on perceived efficacy of physiotherapy or the use of complementary and alternative medicine...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2017.01.002
更新日期：2017-02-01 00:00:00
abstract：BACKGROUND:The frequency and long-term prognosis of relapsing multiple sclerosis (RMS) never receiving disease-modifying treatment (DMT) is unclear. METHODS:We included 1186 RMS patients with a mean of 17.4 years follow-up and divided them into patients treated with any DMT (DMT) and patients untreated by shared (USD)...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2019.101908
更新日期：2019-12-23 00:00:00
abstract：BACKGROUND:Fingolimod (Gilenya, Novartis, Basel Switzerland) 0.5 mg orally once-daily is widely used for relapsing-remitting multiple sclerosis. Patients are usually screened four months after starting fingolimod for fingolimod-associated macular oedema (FAME). Large registration trials with stringent eligibility crite...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2020.102125
更新日期：2020-07-01 00:00:00
abstract：BACKGROUND:Multiple Sclerosis (MS) has been associated with several immune-mediated diseases but the mechanisms that explain such associations, as well as their implications in clinical practice and treatment are rarely discussed. CASE PRESENTATION:We report the case of a patient with a history of MS since she was 27 ...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2019.02.020
更新日期：2019-05-01 00:00:00
abstract：BACKGROUND:Whilst there is a broad selection of drugs licensed as disease modifying treatments (DMTs) for people with relapsing multiple sclerosis (pwRMS), access to DMTs remains restricted, particularly for people with progressive MS (pwPMS). Cladribine has shown efficacy at all stages of MS. Following withdrawal from...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2018.11.001
更新日期：2019-01-01 00:00:00
abstract：BACKGROUND:The epidemiology of multiple sclerosis (MS) and neuromyelitis optica (NMO) remains to be clarified or updated in many parts of Asia. This study aims to investigate the epidemiology and comorbidities of MS and NMO during 2001-2015 in Taiwan. METHODS:We conducted a retrospective nationwide population-based st...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2020.102425
更新日期：2020-10-01 00:00:00
abstract：BACKGROUND:Fatigue is a common and disabling symptom of multiple sclerosis (MS) patients. Structural changes in several brain areas have been reported to correlate with fatigue in MS patients but none consistently. OBJECTIVE:To study the association between global and regional measures of brain atrophy and fatigue in ...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2015.10.006
更新日期：2016-01-01 00:00:00
abstract：:We present a 26 year old Pakistani lady with first presentation of a demyelinating event, presenting as Parinaud's syndrome. The video demonstrates a convergence-retraction nystagmus on upgaze and failure of accommodation, and her brain imaging confirms a corresponding pre-tectal contrast enhancing T2 hyperintense les...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2013.09.003
更新日期：2014-05-01 00:00:00
abstract：OBJECTIVES:To evaluate the effect of intravenous immunoglobulins (IVIG) on prevention of postpartum relapses in women with relapsing-remitting multiple sclerosis (RRMS). METHODS:This was a retrospective study performed in Ljubljana, Slovenia where the practice for all pregnant women with RRMS is to receive IVIG after ...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章,多中心研究
doi：10.1016/j.msard.2019.101519
更新日期：2020-02-01 00:00:00
abstract：:This report presents the 4th documented case worldwide of herpes simplex encephalitis in multiple sclerosis (MS) patients treated with natalizumab and the first case in the UK. Natalizumab is licensed for relapsing remitting multiple sclerosis in patients with high disease activity despite treatment with interferon-be...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2013.02.006
更新日期：2013-10-01 00:00:00
abstract：BACKGROUND:It has been suggested that comorbidity in subjects with multiple sclerosis (MS) increases the risk of hospitalizations, although few studies have examined this, and rarely in an incident population. METHODS:Incident MS cases were identified retrospectively from administrative data in Saskatchewan, Canada (1...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2020.101955
更新日期：2020-05-01 00:00:00
abstract：:61-year-old woman with Neuromyelitis optica (NMO) diagnosis treated with rituximab was referred to our hospital with severe hypovolemic shock and anasarca. The laboratory findings showed marked hemoconcentration and a decrease in total serum protein. She developed a multiple organ failure and died three hours later. W...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2017.06.001
更新日期：2017-08-01 00:00:00
abstract：OBJECTIVE:Infusion-associated reactions (IARs) occur in >90% patients with multiple sclerosis (MS) treated with alemtuzumab. We aimed to study the frequency of IARs at 2 sites using 5 days of steroids (1g/day of IV methylprednisolone), but otherwise distinct protocols. METHODS:This was retrospective chart review of 38...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章,多中心研究
doi：10.1016/j.msard.2017.07.019
更新日期：2017-10-01 00:00:00
abstract：BACKGROUND:Many natalizumab treated patients experience end of dose interval (EDI) symptoms towards the end of the administration cycle. Natalizumab has previously shown to influence cytokine profiles in relapsing remitting MS patients. We hypothesize that EDI symptoms might be explained by variability in serum cytokin...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2020.102020
更新日期：2020-06-01 00:00:00
abstract：:Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is an autoimmune disorder characterised by psychiatric symptoms, movement disorder and seizures often evolving into a severe encephalopathy. An overlap has recently been recognised between anti-NMDAR encephalitis and inflammatory demyelinating disorders, particul...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2016.12.009
更新日期：2017-02-01 00:00:00
abstract：BACKGROUND:Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system (CNS) that preferentially targets the spinal cord and optic nerves. Increasing disability is accrued with each inflammatory attack. Disability has been shown to be an independent predictor of poor quality of...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章,meta分析
doi：10.1016/j.msard.2018.12.011
更新日期：2019-02-01 00:00:00
abstract：BACKGROUND:Underestimation of relapse in multiple sclerosis (MS) is detrimental to the patient as well as to their relationship with their MS healthcare professional (HCP). OBJECTIVE:To obtain direct insight into relapse prevalence, symptoms, and HCP engagement from patients with MS who responded to the Multiple Scler...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2018.09.002
更新日期：2018-11-01 00:00:00
abstract：BACKGROUND:Daytime sleepiness is a common symptom of multiple sclerosis (MS) that may jeopardize safe driving. Our aim was to compare daytime sleepiness, recorded in real-time through eyelid tracking, in a simulated drive between individuals with MS (iwMS) and healthy controls. METHODS:Fifteen iwMS (age = median (Q1 -...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2020.102607
更新日期：2020-10-31 00:00:00
